Internal Med & Specialtys Flashcards
osteoarthritis - CF (pain, stiffness, swelling)
Pain after activity towards the end of the day, relieved by rest.
Stiffness after activity and early morning
» LASTS <30 min
Swelling absent
osteoarthritis - management
First line: paracetamol
Second line: NSAID or COX2 (celecoxib)
Intraarticular GCS (flare up of knee OA)
Surgery (OA knee, shoulder)
Glucosamine, chondroitin, vit D, omega 3 fatty acids not recommended.
Avoid long term opioids, oral GCS, gold, antimalarias , cytotoxic
Exercise, diet, rest, heat, physiotherapy, occupational therapy, braces, orthotics, walking aids.
RA - Dx and autoantibodies for Dx
Anti-ccp (best ^^^^ specificity)
The diagnosis of RA is made on the basis of clinical presentation, in association with autoantibodies and evidence of systemic inflammation (eg elevated ESR and RCP).
The most commonly affected joints include the wrists, metacarpophalangeal joints, proximal interphalangeal joints and metatarsophalangeal joints.
The findings are generally symmetric
> The carpometacarpal and distal interphalangeal joints are not typically affected. Other large joints may also be affected by rheumatoid arthritis.
RA - extra articular manifestations
Rheumatoid nodules
Alopecia
Livedo reticularis
Chronic disease anaemia
Scleritis, episcleritis
Xerostomia
Pericarditis
RA - Pain management
NSAID or paracetamol for pain management
RA - Definitive management
- Methotrexate DMARD improves long-term outcome (consider folic acid supplementation):
methotrexate 10 mg orally, on one specified day once weekly, increasing up to 25 mg orally or subcutaneously, on one specified day once weekly
PLUS
folic acid 5 to 10 mg orally, per week (preferably not on the day methotrexate is taken).
Glucocorticosteroids for flare of RA (consider injections if large joints are involved).
Hydroxychloroquine is used in combined therapy: methotrexate + sulfasalazine + hydroxychroroquine.
Etarnacept biological DMARD is used in combination with methotrexate if monotherapy is not effective. Increased risk of infection (tuberculosis, atypical pneumonia, listeriosis).
Gout - ttx of acute attack
Avoid initiation or changing the dose of Allopurinol during an acute attack.
In acute attack Allopurinol can be safely continued.
In acute attack: NSAID or Colchicine if ulcer, systemic GCS if renal failure.
1 - a local corticosteroid injection at up to a maximum of two affected sites (see Table 12.9 for example doses)
OR
1 - NSAID orally, until symptoms abate (typically 3 to 5 days) (see Table 12.7 for dosing; the upper end of the dosing range is often required)
OR
1 - prednis(ol)one 15 to 30 mg orally, daily until symptoms abate (typically 3 to 5 days) [Note 2]
OR
2 (due to adverse effects, mostly GI) - colchicine 1 mg orally initially, then 500 micrograms 1 hour later, as a single one-day course (total dose is 1.5 mg).
Gout - when to consier GCS injections?
Consider GCS injections if one or two joints are involved (maximum 2)
Gout -when to begin Allopurinol after acute attack?
Commence Allopurinol (if needed) 6 8 weeks after an acute attack.
Gout - diagnosis
Aspiration of an affected joint, bursa or tophus is required to confirm the diagnosis of gout.
It show the presence of needle shaped negatively-birefringent uric acid crystals (monosodium urate crystals)
Serum uric concentration should be measured in all patients with suspected gout. However, the presence of hyperuricaemia alone is insufficient to diagnose gout and, in patients with acute gout, serum uric concentration may be normal. Other than the presence of tophi, individual clinical features (eg history of painful or swollen big toe, unilateral podagra) have a low diagnostic utility.
Response to colchicine does not replace aspiration in the diagnosis of gout; it can support a diagnosis of crystal arthritis, but does not distinguish between gout and acute calcium pyrophosphate crystal arthritis.
Gout - serum uric acid target
The target serum uric acid concentration is less than 0.36 mmol/L (6 mg/dL) for patients with non-tophaceous gout, and less than 0.30 mmol/L (5 mg/dL) for patients with tophaceous gout
Measure serum uric acid concentration monthly during the dose titration phase
Gout - First-line urate-lowering therapy
allopurinol 50 mg orally, daily for 4 weeks; then increase the daily dose by 50 mg every 2 to 4 weeks or by 100 mg every 4 weeks to achieve the target serum uric acid concentration, up to a maximum maintenance dose of 900 mg daily.
- If the target serum uric acid concentration cannot be achieved with allopurinol monotherapy:
probenecid 250 mg orally, twice daily for 1 week, then increase to 500 mg twice daily; then increase the daily dose by 500 mg every 4 weeks to achieve the target serum uric acid concentration, up to a maximum maintenance dose of 2 g daily in divided doses.
Gout - Flare prophylaxis when starting or increasing urate-lowering therapy
1 - colchicine 500 micrograms orally, once or twice daily. Reduce dosage in renal impairment
OR
2 - NSAID orally (see Table 12.7 for dosing; the lower end of the dosing range is usually adequate)
Gout - alternatives to colchicine
Febuxostat as an alternative urate lowering therapy .
It has the same mechanism as allopurinol (reduces the amount of uric acid made by body cells).
This would therefore be appropriate in patients with allopurinol rash or hypersensitivity to allopurinol.
»C/I in liver failure and pre-existing major cardiovascular disease
Probenecid the second line agent. Provides hyperexcretion of uric acid by blocking renal tubular reabsorption.
»C/I in urate nephrolithiasis.
Allopurinol desensitization if no alternative therapeutic options.
1febuxostat 40 mg orally, daily for 2 to 4 weeks; then increase the daily dose by 40 mg every 2 to 4 weeks to achieve the target serum uric acid concentration, up to a maximum maintenance dose of 120 mg daily
OR
2probenecid 250 mg orally, twice daily for 1 week, then increase to 500 mg twice daily; then increase the daily dose by 500 mg every 4 weeks to achieve the target serum uric acid concentration, up to a maximum maintenance dose of 2 g daily in divided doses.
Gout - indication for surgical ttx
Surgery: in destructive changes of joints
One of three surgical treatments is often recommended: tophi removal, joint fusion, or joint replacement.
SLE classification criteria:
Malar rash
Discoid rash
Photosensitivity
Arthritis (symmetrical, non erosive)
Oral ulcers (painless)
Serositis (pleurisy, pericarditis)
Proteinuria, cellular casts
Intractable headache, seizure, psychosis
Haemolytic anaemia, thrombocytopenia, leukopenia, lymphopenia
Antiphospholipid syndrome
SLE - Disease flare may be accompanied by a rise or decrease in which seromarkers?
antibodies to double-stranded DNA (dsDNA) and a reduction in C3 and C4 complement components
Azathioprine - caution for drug toxicity
hiopurine drugs are metabolised by TPMT. TPMT displays genetic polymorphism resulting in null or decreased enzyme activity (3 14% of people). These polymorphism is associated with»_space;»>increased myelosuppression risk.
Consider an alternative agent or extreme dose reduction of azathioprine for patients with los or deficient TPMT activity. Start at 30 70% of target dose for patients with intermediate enzyme activity.
Temporal arteritis - cf
Headache (new onset) throbbing pain unilateral
Scalp tenderness
Jaw claudication (pathognomonic)
Vision problems (sudden visual loss or diplopia)
Loss of pulsation of temporal artery
Malaise
The features of giant cell arteritis may be vague and nonspecific; in patients with systemic features such as weight loss, fevers, malaise and generalised pain and stiffness,
Strong association with Polymyalgia Rheumatica (50%):
Temporal arteritis - Ix and Mx
Investigation: first step: ESR/CRP. best step: biopsy of artery at least 2 cm, multiple sections (giant cells).
Treatment: High dose prednisolone (40 60 mg) orally.
Urgent! Referral to ophthalmologist.
polymyalgia rheumatica - Cf
Pain or aching is usually felt in the large muscle groups, especially around the shoulders and hips.
Patients complain of an inability to turn over in bed and of great difficulty getting out of bed. The stiffness tends to improve after a hot shower, and with activity.
Other symptoms may include:
> Stiffness, especially in the morning
and after resting
Weakness
Fatigue
Generally feeling ill
Mild fevers (occasionally)
Weight loss
A high erythrocyte sedimentation rate (ESR) is common among patients with PMR, but is not always present.
Quick recovery and disappearance of symptoms after treatment with low-dose corticosteroids.
ankylosing spondylitis - management
Physiotherapy for exercises, hydrotherapy, stretching program, postural exercises. Appropriate physiotherapy slows deterioration in spinal function.
Smoking cessation
NSAIDs are the first line treatment for patients without IBD or renal impairment
TNF-ALFA inhibitors, such as Infliximab and Adalimumab, are the first line for patients with concurrent IBD or recurrent anterior uveitis. Second line in patients with insufficient response to TWO nsaids.
Exception: etarnecept for IBD
Local GCS - isolated active sacroilitis or active enthesitis.
Sulfasalazine can be used if NSAIDs and exercise are not effective, It has little effect in spinal disease, but can be useful for an associated peripheral arthritis
ankylosing spondylitis - CF
Articular and peri-articular features
enthesitis (inflammation at the sites of tendon and ligament attachment to bone)
spondylitis (inflammation of the spine) characterised by sacroiliitis (inflammation of sacroiliac joints)
peripheral arthritis that, characteristically:
is oligoarticular
is asymmetrical
affects the lower limbs
affects large joints
dactylitis (inflammation of a whole finger or toe, ‘sausage digits’)
Possible extra-articular features:
psoriasis-like skin and nail lesions
»»conjunctivitis or acute anterior uveitis (MOST COMMON)
chronic gastrointestinal inflammation
chronic genitourinary inflammation
What vasculitis is implicated in high C-Anca levels?
Wegener’s - Granulomatosis with polyangiitis